|Videos|April 12, 2016

Current Treatment Methods for Hepatitis C

Charitha Gowda, MD MPH, infectious diseases physician at Penn Presbyterian Medical Center discusses the current treatment methods for hepatitis C.

Charitha Gowda, MD, MPH, infectious diseases physician at Penn Presbyterian Medical Center, and post-doctoral research fellow in the Division of Infectious Diseases and Center for Clinical Epidemiology & Biostatistics at the University of Pennsylvania, discusses the current treatment methods for hepatitis C.


Related to this article

The Prospective Emergence of XDR Shigella Beyond High-Risk Groups
Los Angeles has been experiencing this challenging bacteria in recent years with the potential of it becoming carbapenem-resistant in the future. Shaun Yang, PhD, D(ABMM), FIDSA, MLS(ASCP), provides commentary about his team's work in this area and the role of genomic sequencing to uncover this troublesome pathogen.
Cefiderocol Continues to Show Activity Against Resistant Gram-Negative Infections
Shionogi data presented at IDWeek 2026 demonstrated a 76.7% clinical response with cefiderocol in carbapenem-resistant respiratory infections and high in vitro activity against resistant P aeruginosa VAP isolates. Christine Slover, PharmD, vice president, Infectious Diseases US Medical Affairs, Shionogi, offers insights on the data as well as clinical considerations for providers when weighing the antibiotic for patients.